期刊文献+

青蒿素联合硫酸亚铁对小鼠移植乳腺癌MT40作用

The Effects of Artemisinin Combined with Ferrous Sulfate on Transplanted MT40 Cells of Mice
原文传递
导出
摘要 目的探讨青蒿素联合硫酸亚铁对小鼠移植乳腺癌MT40作用。方法建立小鼠移植乳腺癌MT40动物模型,将造型成功30只小鼠随机分成5组,每组6只,即青蒿素实验组、硫酸亚铁对照组、青蒿素联合硫酸亚铁组、阳性对照组(丝裂毒素组)、阴性对照组。制作青蒿素联合硫酸亚铁、硫酸亚铁、青蒿素、阴性对照、阳性对照组小鼠移植乳腺癌MT40荷瘤鼠肿瘤生长曲线,计算各组肿瘤体积倍增时间;计算各组抑瘤率;TUNEL检测各组肿瘤组织细胞凋亡率。结果与阴性对照组相比,各组小鼠移植乳腺癌MT40生长曲线受到抑制。与阴性对照组比较,青蒿素实验组抑制肿瘤的生长,抑瘤率42.2%(P〈0.05),阳性对照组也能抑制肿瘤生长,抑瘤率为44.6%(P〈0.01),青蒿素联合硫酸亚铁实验组抑制肿瘤生长作用更加显著,抑瘤率为55.1%(P〈0.05)。肿瘤体积倍增时间延长,各组瘤体倍增时间为:阴性对照组2.77d,硫酸亚铁对照组2.71d,青蒿素实验组3.45d,青蒿素+硫酸亚铁组3.86d,阳性对照组3.44d。TUNEL检测各实验组肿瘤组织细胞凋亡,阴性对照组及硫酸亚铁对照组可见零星细胞凋亡,青蒿素实验组、青蒿素联合硫酸亚铁实验组及阳性对照组见较多细胞凋亡,青蒿素实验组肿瘤细胞凋亡率21.23%,青蒿素联合硫酸亚铁实验组肿瘤细胞凋亡率34.25%,阳性对照组肿瘤细胞凋亡率为17.42%。结论青蒿素联合硫酸亚铁对小鼠移植MT40具有明显抑制、诱导凋亡作用。 Objective To explore the effects of artemisinin combined with ferrous sulfate on transplanted MT40 cells. Methods Transplanted MT40 mice model was established. 30 modeling mice were divided into 5 groups : arte- misinin group, ferrous sulfate group, artemisinin combined with ferrous sulfate group, negative control group, positive control group. The growth curves of transplanted MT40 were manufactured for every group. Tumor doubling time and tumor inhibition rate were calculated. Cell apoptosis rates were detected by TUNEL. Results Compared with negative control group, growth curves were suppressed in the other groups. Tumor inhibition rate in artemisinin group was 42.2% ( P 〈 0.05 ). Tumor inhibition rate of mitomycin was 44.6% ( P 〈 0.01 ). Tumor inhibition rate in artemisinin combined with ferrous sulfate group was 55.1% (P 〈 0.05 ). Tumor doubling times were prolonged in negative control group(2.77 d), ferrous sulfate group(2.71 d), artemisinin group(3.45 d), artemisinin combined with ferrous sul- fate group(3.86 d), positive control group(3.44 d). Cell apoptosis in negative control group and ferrous sulfate group was scattered. Cell apoptosis rates in artemisinin group, artemisinin combined with ferrous sulfate group and pos- itive control group were 21.23%, 34.25% and 17.42% respectively. Conclusion Artemisinin combined with fer- rous sulfate can inhibit growth and induce apoptosis of transplanted MT40 cells.
出处 《医学新知》 CAS 2015年第5期326-328,331,F0004,共5页 New Medicine
关键词 乳腺癌 青蒿素 硫酸亚铁 Breast cancer Artemisinin Ferrous sulfate
  • 相关文献

参考文献10

  • 1Posner G H, McRiner A J, Paik I H, et al. Anticancer and antimalari-al efficacy and safety of artemisinin - derived trioxane dimers in ro- dents [ J ]. M ed Chem,2004,47 ( 5 ) : 1299.
  • 2Efferth T, Dunstan H, Sauerbrey A,et al. The Anti--malarial Artesu- nat Is Also Active Against -cancer[ J ]. International Journal of On- cology,2001,18(4) :767.
  • 3Yu H P,Cui L,Pan Y J. Reversal of Drug Resistance in Multidrug- resistance MCFT/ADR Cells of Breast Cancer By Artemisinin [ J ]. Acta Med Univ Sci Technol Huazhong,2011,40( 1 ) :91.
  • 4Panieri E. Breast cancer in developing countries[J]. Best Practice & Research Clinical Obstetrics & Gynaecology ,2012,26(2) :283-290.
  • 5邵志敏,沈镇宙.21世纪乳腺癌治疗的展望[J].中国癌症杂志,2005,15(5):405-407. 被引量:29
  • 6徐鹏.乳腺癌靶向给药系统的研究进展[J].中国现代药物应用,2012,6(3):124-126. 被引量:4
  • 7徐继红,章元沛.青蒿素类药物的药理和毒理(综述)[J].浙江医科大学学报,1996,25(1):43-46. 被引量:13
  • 8Yang D C, Wang F,Elliott R L, et al. Expression of transferrin recep- tor and ferritin H - chain mRNA are associated with clinical and his- topathological prognostic indicators in breast cancer [ J ]. Anticancer Res,2001,21 (IB) :541.
  • 9Weinstein R E, Bond B H, Siberberg B K. Tissue ferritin concentra- tion in carcinoma of the breast [J ]. Cancer, 1982,50 ( 11 ) :2406.
  • 10Efferth T, Oesch F. Oxidative stress response of tumor ceils : microar- ray- based comparison between artemisinins and anthracyclines [ J]. Biochem Pharmaco1,2004,68 ( 1 ) :3-10.

二级参考文献33

  • 1靳永刚,滕翕和,孙存普.自由基与青蒿琥酯毒性机理[J].中国药理学与毒理学杂志,1989,3(2):138-143. 被引量:11
  • 2钱皓,凌沛学,王凤山,张天民.脂质体靶向治疗恶性瘤的应用研究进展[J].食品与药品,2007,9(03A):46-49. 被引量:6
  • 3Wong NS,Anderson BO,Khoo KS,et al.Breast cancer in developing countries.Lancet,2009,374(9701):1567.
  • 4Lubbea S,Alexiou C,Bercemann C.Clinical application of magnetic drug targeting.Surg Res,2001,95(2):200-206.
  • 5Embleton MJ.Drug by monocional antibodiest.Br J Cancer,1987,55(3):227-231.
  • 6Foged C,Nielsen HM,Frokjaer S.Liposomes for phospholipase A2 triggered siRNA release:preparation and in vitro test.Int J Pharm,2007,331(2):160-166.
  • 7Vasir JK,Labhasetwar V.Targeted drug delivery in cancer therapy.Technol Cancer Res Treat,2005,4(4):363-374.
  • 8Van Vlerken LE,Duan Z,Little SR,et al.Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model.Mol Pharm,2008,5(4):516-526.
  • 9Onyüksel H,Jeon E,Rubinstein I.Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells.Cancer Lett,2009,274(2):327-330.
  • 10Shuhendler AJ,Cheung RY,Manias J,et al.A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anticancer synergy in multidrug resistant human breast cancer cells.Breast Cancer Res Treat,2010,119(2):255-269.

共引文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部